<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PHENSUXIMIDE</span><br/>(fen-sux'i-mide)<br/><span class="topboxtradename">Milontin<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anticonvulsant succinimide</span><br/><b>Prototype: </b>Ethosuximide<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Succinimide derivative reportedly less potent and less effective than other drugs of this class. Reduces the frequency of
         epileptiform attacks.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Apparently depresses the motor cortex and elevates the threshold of CNS sensitivity to seizure activity, thus lessening the
         incidence of seizure activity.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Management of petit mal epilepsy (absence seizures) and with other anticonvulsants when other forms of epilepsy coexist with
         petit mal.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Intermittent porphyria; liver or kidney disease; pregnancy (category D), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Absence Seizures</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.51 g b.i.d. or t.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give consistently with respect to time of day.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Drowsiness, dizziness, ataxia,</span> muscle weakness, flushing, periorbital edema, <span class="typehead">GI:</span> <span class="speceff-common">Anorexia, nausea, vomiting.</span> <span class="typehead">Urogenital:</span> Reversible nephropathy. <span class="typehead">Hematologic:</span> <span class="speceff-life">Granulocytopenia</span>. <span class="typehead">Skin:</span> Alopecia, pruritus, skin rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Carbamazepine</b> decreases phensuximide levels; <b>isoniazid</b> significantly increases phensuximide levels; levels of both <b>phenobarbital</b> and phensuximide may be altered with increased seizure frequency. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 14 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted slowly in urine; small amounts excreted in bile and feces. <span class="typehead">Half-Life:</span> 512 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor weight, especially in children, since anorexic effects of drug might cause weight loss.</li>
<li>Lab tests: Perform baseline and periodic liver and kidney function tests. Perform periodic blood tests, especially with long-term
            therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report onset of skin rash or other unusual symptoms to physician.</li>
<li>Be aware that phensuximide may color urine pink, red, or red-brown.</li>
<li>Do not use OTC drugs unless the physician approves; loss of seizure control can be induced by ingredients in some popular
            OTC drugs.
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>